

Larry Junck

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6320894/publications.pdf>

Version: 2024-02-01

40
papers

1,524
citations

471509

17
h-index

501196

28
g-index

41
all docs

41
docs citations

41
times ranked

2181
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative study of radiologists vs machine learning in differentiating biopsy-proven pseudoprogression and true progression in diffuse gliomas. <i>Neuroscience Informatics</i> , 2022, , 100088.	4.5	0
2	Climate change and epilepsy: Insights from clinical and basic science studies. <i>Epilepsy and Behavior</i> , 2021, 116, 107791.	1.7	30
3	Lepto mets: loads of data. <i>Neuro-Oncology</i> , 2021, 23, 1044-1045.	1.2	0
4	A Phase 2 Study of Dose-intensified Chemoradiation Using Biologically Based Target Volume Definition in Patients With Newly Diagnosed Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 792-803.	0.8	23
5	Metabolic Tumor Volume Response Assessment Using (11)C-Methionine Positron Emission Tomography Identifies Glioblastoma Tumor Subregions That Predict Progression Better Than Baseline or Anatomic Magnetic Resonance Imaging Alone. <i>Advances in Radiation Oncology</i> , 2020, 5, 53-61.	1.2	11
6	Discriminating pseudoprogression and true progression in diffuse infiltrating glioma using multi-parametric MRI data through deep learning. <i>Scientific Reports</i> , 2020, 10, 20331.	3.3	36
7	BRAINSTORM: A Multi-Institutional Phase 1/2 Study of RRx-001 in Combination With Whole Brain Radiation Therapy for Patients With Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 478-486.	0.8	6
8	Safety Profile of Maintenance Obinutuzumab in Patients with Primary CNS Lymphoma in Complete Response. <i>Blood</i> , 2020, 136, 12-12.	1.4	1
9	Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , 2019, 21, 571-584.	1.2	114
10	Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 143, 313-319.	2.9	11
11	ATIM-44. A PHASE I FIRST-IN-HUMAN TRIAL OF TWO ADENOVIRAL VECTORS EXPRESSING HSV1-TK AND FLT3L FOR TREATING NEWLY DIAGNOSED RESECTABLE MALIGNANT GLIOMA: THERAPEUTIC REPROGRAMMING OF THE BRAIN IMMUNE SYSTEM. <i>Neuro-Oncology</i> , 2019, 21, vi11-vi11.	1.2	4
12	NF1 glioblastoma clonal profiling reveals <i>KMT2B</i> mutations as potential somatic oncogenic events. <i>Neurology</i> , 2019, 93, 1067-1069.	1.1	11
13	First-in-human phase I trial of the combination of two adenoviral vectors expressing HSV1-TK and FLT3L for the treatment of newly diagnosed resectable malignant glioma: Initial results from the therapeutic reprogramming of the brain immune system.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2019-2019.	1.6	15
14	Leptomeningeal metastases: a RANO proposal for response criteria. <i>Neuro-Oncology</i> , 2017, 19, now183.	1.2	157
15	Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of CNS oncology. <i>CNS Oncology</i> , 2017, 6, 1-3.	3.0	0
16	Our panel of experts highlights the most important research articles across the spectrum of topics relevant to the field of CNS oncology. <i>CNS Oncology</i> , 2017, 6, 85-87.	3.0	0
17	Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. <i>Translational Research</i> , 2017, 188, 27.e1-27.e14.	5.0	12
18	Comparison of Diffusion Tensor Imaging and Magnetic Resonance Perfusion Imaging in Differentiating Recurrent Brain Neoplasm From Radiation Necrosis. <i>Academic Radiology</i> , 2016, 23, 569-576.	2.5	21

#	ARTICLE	IF	CITATIONS
19	Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 305-311.	0.8	18
20	Primary CNS lymphoma; a review of the University of Michigan experience 2004-2013.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13012-e13012.	1.6	0
21	Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of CNS oncology. <i>CNS Oncology</i> , 2014, 3, 105-107.	3.0	0
22	Impact of Perfusion Map Analysis on Early Survival Prediction Accuracy in Glioma Patients. <i>Translational Oncology</i> , 2013, 6, 766-774.	3.7	27
23	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of CNS oncology.. <i>CNS Oncology</i> , 2013, 2, 115-116.	3.0	0
24	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of CNS oncology.. <i>CNS Oncology</i> , 2013, 2, 219-221.	3.0	0
25	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of CNS oncology. <i>CNS Oncology</i> , 2013, 2, 11-12.	3.0	0
26	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of CNS oncology. <i>CNS Oncology</i> , 2012, 1, 121-122.	3.0	0
27	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of CNS oncology. <i>CNS Oncology</i> , 2012, 1, 19-20.	3.0	0
28	Clinical trials in neuro-oncology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 104, 417-434.	1.8	1
29	Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. <i>Neuro-Oncology</i> , 2008, 10, 162-170.	1.2	362
30	Differentiation of Lewy body dementia from Parkinson's disease with [C-11]DTBZ PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S393-S393.	4.3	0
31	Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. <i>Neuro-Oncology</i> , 2004, 6, 44-54.	1.2	70
32	Decreased striatal monoaminergic terminals in multiple system atrophy detected with positron emission tomography. <i>Annals of Neurology</i> , 1999, 45, 769-777.	5.3	46
33	The Significance of Family History Status in Relation to Neuropsychological Test Performance and Cerebral Glucose Metabolism Studied with Positron Emission Tomography in Older Alcoholic Patients. <i>Alcoholism: Clinical and Experimental Research</i> , 1998, 22, 105-110.	2.4	25
34	Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C]Dihydrotrabenazine and positron emission tomography. <i>Annals of Neurology</i> , 1998, 44, 326-333.	5.3	59
35	Effects of abstinence and relapse upon neuropsychological function and cerebral glucose metabolism in severe chronic alcoholism. <i>Journal of Clinical and Experimental Neuropsychology</i> , 1997, 19, 378-385.	1.3	58
36	Effects of Disulfiram on Positron Emission Tomography and Neuropsychological Studies in Severe Chronic Alcoholism. <i>Alcoholism: Clinical and Experimental Research</i> , 1996, 20, 1456-1461.	2.4	28

#	ARTICLE	IF	CITATIONS
37	Spinocerebellar ataxia type 1 with multiple system degeneration and glial cytoplasmic inclusions. Annals of Neurology, 1996, 39, 241-255.	5.3	160
38	Decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography. Annals of Neurology, 1996, 40, 885-892.	5.3	58
39	PET Imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Annals of Neurology, 1989, 26, 752-758.	5.3	158
40	Efficacy and Toxicity with Radiation Field Designs and Concurrent Temozolomide for CNS Lymphoma. Neuro-Oncology Practice, 0, , .	1.6	1